Lorlatinib OverviewLorlatinib (PF-6463922), sold under the brand name Lorbrena in the United States, Canada, and Japan, and Lorviqua in the European Union, is an anti-neoplastic drug developed by Pfizer. It is an orally-administered small molecule inhibitor of ROS1 and ALK. In 2015, FDA granted Pfizer orphan drug status for lorlatinib for the treatment of non-small cell lung cancer (NSCLC). Lorlatinib is able to cross the blood-brain barrier. Clinical studies Several cli...
Read more Lorlatinib Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Lorlatinib
Recent Lorlatinib Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Tablet: 100mg, 25mg
Other drugs which contain Lorlatinib or a similar ingredient: (1 result)
- LORBRENA Lorlatinib